Immuneering (IMRX) Equity Ratio (2020 - 2026)
Immuneering's Equity Ratio history spans 7 years, with the latest figure at 0.96 for Q1 2026.
- On a quarterly basis, Equity Ratio rose 16.45% to 0.96 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.96, a 16.45% increase, with the full-year FY2025 number at 0.94, up 19.96% from a year prior.
- Equity Ratio came in at 0.96 for Q1 2026, up from 0.94 in the prior quarter.
- The five-year high for Equity Ratio was 0.96 in Q1 2026, with the low at 0.72 in Q2 2025.
- Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.91 in 2023.
- Biggest five-year swings in Equity Ratio: soared 241.78% in 2022 and later fell 16.02% in 2025.
- Year by year, Equity Ratio stood at 0.9 in 2022, then dropped by 1.65% to 0.88 in 2023, then fell by 11.08% to 0.79 in 2024, then grew by 19.96% to 0.94 in 2025, then rose by 2.08% to 0.96 in 2026.
- Business Quant data shows Equity Ratio for IMRX at 0.96 in Q1 2026, 0.94 in Q4 2025, and 0.95 in Q3 2025.